NCT06238466View on ClinicalTrials.gov

A Study to Investigate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AZD1705 in Participants With Dyslipidemia

PHASE1Active, not recruitingINTERVENTIONAL
Enrollment

96

Participants

Timeline

Start Date

January 16, 2024

Primary Completion Date

December 2, 2025

Study Completion Date

December 2, 2025

Conditions
Cardiovascular
Interventions
DRUG

AZD1705

Participants will receive AZD1705 subcutaneously on Day 1 in Part A, and Days 1 and 29 in Part B.

OTHER

Placebo

Participants will receive placebo on Day 1 in Part A, and Days 1 and 29 in Part B.

Trial Locations (5)

21225

Research Site, Baltimore

32216

Research Site, Jacksonville

32789

Research Site, Winter Park

78229

Research Site, San Antonio

91206

Research Site, Glendale

Sponsors

Lead Sponsor

AstraZeneca

Collaborators (1)

Parexel
All Listed Sponsors
collaborator

Parexel

INDUSTRY

lead

AstraZeneca

INDUSTRY

NCT06238466 - A Study to Investigate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AZD1705 in Participants With Dyslipidemia | Biotech Hunter | Biotech Hunter